About Keryx Biopharmaceuticals, Inc. Keryx Biopharmaceuticals, Inc., with headquarters in Boston, Massachusetts, is focused on the development and commercialization of innovative medicines that provide unique and meaningful advantages to people with kidney disease. The Keryx team consists of approximately 200 committed people working with passion to advance the care of people with this complex disease. This dedication has resulted in two FDA-approved indications for Keryx’s first medicine, Auryxia® (ferric citrate) tablets. For more information about Keryx, please visit www.keryx.com. About BioVectra BioVectra is a CDMO that serves pharmaceutical and biotech companies with full-service cGMP outsourcing solutions for intermediates and active pharmaceutical ingredients. An innovative and reliable service partner with a strong regulatory history, BioVectra has over 45 years of experience specializing in: GMP Microbial Fermentation & Purification Complex Chemistry Process & Analytical Development For more information about BioVectra, please visit www.biovectra.com. Media Contact Jordan MacGregor Marketing and Communications Manager jmacgrego[email protected] 902-566-9116 ext. 6376 www.biovectra.com]]>
BIONOVA CONTACT
#46 1344 Summer Street
Halifax, Nova Scotia
Canada B3H 0A8
Phone: 902-421-5705
Fax: 902-421-2733
Email: [email protected]
Halifax, Nova Scotia
Canada B3H 0A8
Phone: 902-421-5705
Fax: 902-421-2733
Email: [email protected]

Recent Posts
- NEWS RELEASE: Doris Grant appointed Vice President Business Development and Strategy at BioNova
- MARS VR Lab
- Workinsights
- NEWS RELEASE: BioNova Announces MycoFutures North Atlantic as the Winner of the Eleventh Annual BioInnovation Challenge (BIC) at BioPort 2021
- NEWS RELEASE: BioNova’s BioPort 2021 Conference for Health and Life Sciences Kicks-Off Today
Business Wire National BioTech News
- Oragenics Project to Develop a Variant-Agnostic Protein Antigen for Use in its COVID-19 Intranasal Vaccine Receives Funding from CQDM
- BIOQuébec and MassBio Renew Their Memorandum of Cooperation and Collaboration
- MEDiC Life Sciences Announces Collaboration with Bristol Myers Squibb on Tumor Target Discovery
- At BIO 2023, Canada Showcases Multiple Strengths as a Biopharma Powerhouse
- Breast Cancer Canada Announces $3-million Precision Prevention Progress Funding to Princess Margaret Cancer Centre
- Enveric Biosciences Receives Notice of Allowance from USPTO for EVM301 Series of Drug Candidates
- Cybin Announces Scientific Management Transition Following Achievement of Final Adelia Milestones
- Anaergia Signs Contract to Build State-of-the-Art Food Waste and Wastewater Sludge Co-Digestion Facility at Monterey One Water in California
- KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Unresectable Advanced Pleural Mesothelioma
- The Patient Safety Movement Foundation Concludes Its 10th Annual World Patient Safety, Science & Technology Summit
RECENT NEWS
- NEWS RELEASE: Doris Grant appointed Vice President Business Development and Strategy at BioNova February 9, 2023
- MARS VR Lab January 25, 2022
- Workinsights January 25, 2022
- NEWS RELEASE: BioNova Announces MycoFutures North Atlantic as the Winner of the Eleventh Annual BioInnovation Challenge (BIC) at BioPort 2021 November 8, 2021
- NEWS RELEASE: BioNova’s BioPort 2021 Conference for Health and Life Sciences Kicks-Off Today November 2, 2021
- NEWS RELEASE: BioNova Selects Eight Semi-Finalists to Participate in the 11th Annual BioInnovation Challenge August 24, 2021